Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Tenaya Therapeutics, Inc. TNYA
$6.76
-$0.52 (-7.64%)
На 18:04, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
443316276.00000000
-
week52high
7.98
-
week52low
1.64
-
Revenue
0
-
P/E TTM
-3
-
Beta
0.00000000
-
EPS
-3.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mutations; and TN-301, a small molecule inhibitor of histone deacetylase 6 (HDAC6i) for use in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy (gDCM). It is also developing TN-401, an AAV-based gene therapy that addresses genetic arrhythmogenic right ventricular cardiomyopathy (gARVC) caused by plakophilin 2 (PKP2) gene mutations; an AAV-based gene therapy designed to deliver the dwarf open reading frame (DWORF) gene in the heart for DCM; and Reprogramming program, an AAV-based approach for cardiac regeneration to replace heart cells lost in patients experiencing heart failure due to prior myocardial infarction. The company was incorporated in 2016 and is headquartered in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 11 авг 2022 г. |
| HC Wainwright & Co. | Buy | 15 июн 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 17 мая 2022 г. |
| Piper Sandler | Overweight | 24 авг 2021 г. | |
| Morgan Stanley | Overweight | 24 авг 2021 г. | |
| Chardan Capital | Buy | Buy | 11 ноя 2022 г. |
| Canaccord Genuity | Buy | 08 ноя 2022 г. | |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| COLUMN GROUP III GP, LP | A | 9870274 | 69739 | 19 янв 2023 г. |
| GOEDDEL DAVID V | A | 9870274 | 69739 | 19 янв 2023 г. |
| COLUMN GROUP III GP, LP | A | 9800535 | 135688 | 18 янв 2023 г. |
| GOEDDEL DAVID V | A | 9800535 | 135688 | 18 янв 2023 г. |
| COLUMN GROUP III GP, LP | A | 9664847 | 49463 | 17 янв 2023 г. |
| GOEDDEL DAVID V | A | 9664847 | 49463 | 17 янв 2023 г. |
| Burroughs Amy L. | A | 40000 | 40000 | 05 дек 2022 г. |
| Srivastava Deepak | A | 372435 | 230769 | 21 ноя 2022 г. |
| GOEDDEL DAVID V | A | 9615384 | 9615384 | 21 ноя 2022 г. |
| COLUMN GROUP III GP, LP | A | 9615384 | 9615384 | 21 ноя 2022 г. |
Новостная лента
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Buy: Here's What You Should Know
Zacks Investment Research
26 янв 2023 г. в 13:33
Tenaya Therapeutics, Inc. (TNYA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
4 Penny Stocks To Buy In January According To Insiders
PennyStocks
20 янв 2023 г. в 14:14
Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
PennyStocks
14 ноя 2022 г. в 13:33
Analysts say these are penny stocks to buy. Do you agree?
Tenaya Therapeutics to Present Preclinical Data on Its Novel Engineered AAV Capsids for Cardiac Gene Delivery at the ESGCT 29th Annual Congress
GlobeNewsWire
04 окт 2022 г. в 08:30
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced today that it will present new preclinical data on its novel AAV capsids for cardiac gene delivery at the 29th Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), October 11 - 14, 2022 in Edinburgh, Scotland.
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
Business Wire
20 мая 2022 г. в 08:30
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Tenaya Therapeutics announced that it will present preclinical data at the European Society of Cardiology (ESC) Heart Failure 2022 conference.